Get immediate alerts when information breaks in your shares. Declare your 1-week free trial to StreetInsider Premium here.
Vericel Company (NASDAQ: VCEL), a pacesetter in superior therapies for the sports activities drugs and extreme burn care markets, introduced the appointment of Joe Mara as Chief Monetary Officer of the Firm, efficient at this time.
Mr. Mara joins Vericel with over 20 years of economic, strategic and operational expertise, together with greater than 14 years of expertise within the biotech trade. Most just lately, Mr. Mara served as Vice President, Finance and Head of Investor Relations at Biogen Inc. Throughout his tenure at Biogen, Mr. Mara held a number of finance management roles, together with Vice President, International Monetary Planning and Evaluation and Strategic Company Finance and Vice President, U.S. Finance and Operations. Previous to becoming a member of Biogen, Mr. Mara held finance and technique roles within the monetary providers and know-how industries, together with at Thomson Reuters Company and Constancy Investments. Mr. Mara earned a B.A. diploma in Economics and Worldwide Research from Northwestern College and an M.B.A. from the Sloan Faculty of Administration at M.I.T.
“Joe is a confirmed finance and enterprise chief with a observe report of success in operational and strategic finance roles throughout U.S. and world organizations,” stated Nick Colangelo, President and Chief Government Officer of Vericel. “I’m more than happy that Joe is becoming a member of the Vericel government crew at a time when his in depth expertise will assist drive continued robust development and monetary outcomes for the Firm within the years forward.”
“I’m very excited to affix Vericel given its management place in cell remedy and the sports activities drugs and extreme burn care markets, its progressive product portfolio, and the Firm’s important development potential,” stated Mr. Mara. “I stay up for working with the Vericel crew to proceed to supply essential merchandise to sufferers, execute on the Firm’s long-term development technique, and drive continued worth for our shareholders.”